Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defending the Ethical Permissibility of Laryngeal Transplantation.

The American journal of bioethics : AJOB·2026
Same author

Antigen Removal Approach to Murine Larynx Engineering Optimizes Extracellular Matrix Preservation.

The Laryngoscope·2026
Same author

Idiopathic Subglottic Stenosis in Pregnancy: A Case-Control Study of Management and Maternal Safety.

The Laryngoscope·2026
Same author

A Universal Optical Microanalysis Platform Based on Micropipette Tips.

Sensors and actuators. B, Chemical·2026
Same author

Patient Navigation With Hospital Addiction Consultation and Patient-Directed Discharge: Secondary Analysis of a Randomized Clinical Trial.

JAMA network open·2026
Same author

How I Do It: Two Novel, Low-Cost Phonomicrosurgery Models With Open-Source, 3D-Printed Laryngoscopes.

The Laryngoscope·2026
Same journal

Orticochea Flap for Reconstruction of Large Scalp Defects: Outcomes and Technique.

The Laryngoscope·2026
Same journal

Rising Pediatric Button Battery Injuries Despite Safety Efforts: An Analysis of National Injury Data.

The Laryngoscope·2026
Same journal

Laryngeal Nerve Protection Devices in Thyroid Surgery: A Systematic Review and Evidence Synthesis.

The Laryngoscope·2026
Same journal

Practice Patterns for the Management of Pediatric oSDB: What Is the Current National Landscape?

The Laryngoscope·2026
Same journal

Vocal Fold Opening Position Impacts Bowing Measures in Age-Related Vocal Atrophy.

The Laryngoscope·2026
Same journal

Association Between the Modified Frailty Index and Short-Term Total Thyroidectomy Complications.

The Laryngoscope·2026
See all related articles

Related Experiment Video

Updated: Sep 12, 2025

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies
13:37

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies

Published on: March 12, 2014

30.1K

DNA Immunotherapy (INO-3107) Results in Long-Term Surgery Reduction in RRP.

Milan R Amin1, Peter C Belafsky2, Simon R Best3

  • 1Department of Otolaryngology-Head and Neck Surgery, New York University Grossman School of Medicine, New York, New York, USA.

The Laryngoscope
|August 9, 2025
PubMed
Summary
This summary is machine-generated.

INO-3107 immunotherapy demonstrates long-term safety and clinical efficacy in adults with recurrent respiratory papillomatosis (RRP). Treatment significantly reduced the need for surgical interventions and showed a growing complete response rate over two years.

Keywords:
DNA immunotherapyHPV‐11HPV‐6recurrent respiratory papillomatosisreduced surgeries

More Related Videos

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

10.3K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.6K

Related Experiment Videos

Last Updated: Sep 12, 2025

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies
13:37

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies

Published on: March 12, 2014

30.1K
Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

10.3K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.6K

Area of Science:

  • Immunotherapy
  • Otolaryngology
  • Viral Diseases

Background:

  • Recurrent respiratory papillomatosis (RRP) is a rare, chronic disease caused by human papillomavirus (HPV) types 6 and 11.
  • RRP significantly impacts quality of life and necessitates frequent surgical interventions.
  • Current treatments for RRP have limitations, highlighting the need for novel therapeutic approaches.

Purpose of the Study:

  • To assess the long-term safety and clinical effectiveness of INO-3107 immunotherapy in adult patients with RRP.
  • To evaluate the sustained impact of INO-3107 on reducing surgical interventions and improving patient outcomes.
  • To determine the overall safety profile of INO-3107 through extended follow-up.

Main Methods:

  • Retrospective observational extension study (RRP-002) following patients from a previous 52-week study (RRP-001).
  • Inclusion criteria: moderate to severe RRP, ≥2 surgeries in the prior year.
  • INO-3107 administered on Day 0, Weeks 3, 6, and 9, following surgical debulking.

Main Results:

  • 28 of 32 participants completed the study with a median follow-up of 1.8 years (total assessment 2.8 years).
  • No severe adverse events (SAEs) or long-term safety concerns were identified.
  • Mean surgeries reduced from 4.1 (pre-treatment) to 1.7 (Year 1) and 0.9 (Year 2). Complete response rate increased from 28% (Year 1) to 50% (Year 2).

Conclusions:

  • INO-3107 is well-tolerated and offers sustained clinical benefit for adult RRP patients.
  • The immunotherapy effectively reduces the surgical burden associated with RRP.
  • These findings support INO-3107 as a valuable treatment option for adult RRP.